Detalles de la búsqueda
1.
Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities.
Cancer Cell Int;
24(1): 84, 2024 Feb 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402182
2.
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease.
Transl Lung Cancer Res;
12(8): 1661-1701, 2023 Aug 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37691866
3.
SDH mutations, as potential predictor of chemotherapy prognosis in small cell lung cancer patients.
Discov Oncol;
14(1): 89, 2023 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37273084
4.
The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC.
Open Life Sci;
18(1): 20220533, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36910471
5.
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.
J Thorac Oncol;
18(5): 628-639, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36646210
6.
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01).
J Clin Oncol;
41(3): 651-663, 2023 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36206498
7.
Risk factors and prognostic role of renal adverse event in patients receiving immune checkpoint inhibitor therapy: analysis of data from a retrospective cohort study.
Ann Transl Med;
10(18): 967, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36267724
8.
Efficacy, prognosis and safety analysis of anti-PD-1/PD-L1 inhibitor rechallenge in advanced lung cancer patients: a cohort study.
Transl Lung Cancer Res;
11(6): 1038-1050, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35832441
9.
PIV and PILE Score at Baseline Predict Clinical Outcome of Anti-PD-1/PD-L1 Inhibitor Combined With Chemotherapy in Extensive-Stage Small Cell Lung Cancer Patients.
Front Immunol;
12: 724443, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34777341
10.
Two severe adverse events triggered by an anti-PD-1 immune checkpoint inhibitor in an advanced lung cancer patient: a case report and review of the literature.
Ann Transl Med;
9(16): 1358, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34532495
11.
Genomic landscape and evolution of arm aneuploidy in lung adenocarcinoma.
Neoplasia;
23(9): 870-878, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34303217
12.
Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
J Thorac Oncol;
16(11): 1959-1963, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34265433
13.
Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
J Thorac Oncol;
16(8): 1403-1414, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33915252
14.
EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAFV600E mutation: a case report and review of literature.
Cancer Drug Resist;
4(4): 1019-1027, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35582379
15.
Case Report: A 91-Year-Old Patient With Non-Small Cell Lung Cancer Harboring MET Y1003S Point Mutation.
Front Med (Lausanne);
8: 772998, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35174181
16.
Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy.
J Thorac Oncol;
14(5): e85-e88, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30711650
17.
A detrimental mutation on USP40 unlocks the tumorigenesis in a rare case of lung cancer.
Int J Clin Exp Pathol;
12(3): 740-749, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31933881
18.
Monitoring antiangiogenesis of bevacizumab in zebrafish.
Drug Des Devel Ther;
12: 2423-2430, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30122900
19.
Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity.
Cell Physiol Biochem;
49(1): 235-244, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30138935
20.
Significance of NLDA, the commixed index of inflammation, immune responses, hemostasis, and nutrition, for predicting metastatic non-small cell lung cancer prognosis and metastases.
Oncotarget;
8(47): 81978-81993, 2017 Oct 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29137238